Roche: Tecentriq fails clinical trial

(CercleFinance.com) - Roche announced on Friday the failure of a phase III clinical trial of its immunotherapy Tecentriq plus paclitaxel in metastatic breast cancer.


The IMpassion131 study failed to meet its primary endpoint of progression-free survival in patients with triple-negative metastatic breast cancer with expression of the PD-L1 marker compared to paclitaxel coupled with placebo.

In a statement, the pharmaceutical group said it was "disappointed" by these results.

However, on Friday morning, the oncology heavyweight's share was still up 0.3%, placing it as a winner in the Swiss SMI index, which was just afloat, adding 0.1%.



Copyright (c) 2020 CercleFinance.com. All rights reserved.